Review Article

Systemic Inflammatory Markers for Predicting Overall Survival in Patients with Osteosarcoma: A Systematic Review and Meta-Analysis

Xiaotong Song,1 Hao Zhang,1 Fanxing Yin,1 Panpan Guo,1 Xiaocheng Yang,1 Jinzhu Liu,2 Yanshuo Han1,1 and Zhaozhou Ren3

1School of Life and Pharmaceutical Sciences, Dalian University of Technology, Panjin 124001, China
2Department of Orthopedic Surgery, The Third People’s Hospital of Shenzhen, Shenzhen 518000, China
3Department of Orthopaedic Surgery, Shengjing Hospital of China Medical University, Shenyang 110001, China

Correspondence should be addressed to Yanshuo Han; yanshuohan@dlut.edu.cn and Zhaozhou Ren; zhaozhou.ren@yahoo.com

Received 2 June 2021; Revised 6 September 2021; Accepted 25 September 2021; Published 21 October 2021

Academic Editor: Zhenhan Deng

Copyright © 2021 Xiaotong Song et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Inflammatory markers are associated with tumor genesis and progression, but their prognostic significance in osteosarcoma remains unclear. Therefore, we discussed the prognostic value of related inflammatory markers in osteosarcoma through a meta-analysis and systematic review. These inflammatory markers include C-reactive protein (CRP), neutrophil to lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LMR), platelet to lymphocyte ratio (PLR), and Glasgow prognostic score (GPS).

Methods. The Chinese National Knowledge Infrastructure (CNKI), Wanfang, Chinese Scientific Journals (VIP), PubMed, Embase, and Cochrane libraries were searched. The design of meta-analysis was made based on the PICOS (population, intervention/exposure, control, outcomes, and study design) principles, and STATA 15.1 was used to analyze the data. The Newcastle-Ottawa scale (NOS) was used to assess the quality of included studies. Hazard ratios (HRs) for overall survival (OS) and disease-specific survival (DPS) were extracted for the investigation of the prognostic value of inflammatory markers.

Results. Twelve researches with 2162 osteosarcoma patients were included in total. The pooled results showed that elevated NLR, CRP, and GPS are all greatly related to shortening of OS among patients with osteosarcoma (HR = 1.68, 95% CI: 1.15-2.45; HR = 1.96, P = 0.002, 95% CI: 1.28-3.00; HR = 2.54, P < 0.0001, 95% CI: 1.95-3.31, respectively), and CRP level is significantly associated with shortening of DPS among patients with osteosarcoma (HR = 2.76, 95% CI: 2.01-3.80, P < 0.0001), additionally. However, the correlation between LMR or PLR and the prognosis of osteosarcoma is not statistically significant (HR = 0.60, 95% CI: 0.30-1.18, P = 0.138; HR = 1.13, 95% CI: 0.85-1.49, P = 0.405, respectively). The outcomes of subgroup analysis to NLR and CRP suggested that histology, ethnicity, metastasis, and sample size all have an impact on its prognosis of patients with osteosarcoma. Conclusion. Worsened prognosis may be related to high levels of NLR, CRP, and GPS before treatment rather than LMR or PLR, which can provide the basis for clinicians to judge the outcomes of prognosis. Trial Registration. PROSPERO (CRD42021249954), https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=249954.

1. Introduction

As a greatly malignant bone tumor, osteosarcoma mainly influences adolescents and young adults, accounting for about 45% of all bone sarcomas [1]. The development of integrated chemotherapy in the 1970s increased the overall survival rates by about 50% [2]. Among them, the incidence of osteosarcoma in Europe is 7.3 per million person-years, while 12.2 per 1 million person-years in Asia [3]. In addition, the 5-year survival rate for osteosarcoma in Europe is 61% and 75% in Asia [4]. With the gradual development of clinical practice, the inaccuracy and inadequacy of traditional prognostic elements, such as the presence of tumor grade, metastasis, tumor location, and histological subtypes,
have gradually been exposed [5]. Therefore, identifying more effective prognostic factors will be valuable for stratifying patients with different treatment options and improving survival.

In recent years, according to emerging evidence, systemic inflammatory response is an independent prognostic biomarker among different tumors. Moreover, according to increasing studies, there is a clear association between inflammatory markers and lower survival rates for some tumors such as neutrophil to lymphocyte ratio (NLR), Glasgow prognostic score (GPS), C-reactive protein (CRP), platelet to lymphocyte ratio (PLR), and lymphocyte to monocyte ratio (LMR) [6–9]. However, the predictive effect of these inflammatory indicators on the prognosis of osteosarcoma is unclear. The research of Liu et al. [10] and Xia et al. [11] believed that enhanced NLR is significantly related to the shortening of OS among patients with osteosarcoma, but the study of Huang et al. [12] suggested that NLR cannot be used as a protective factor for osteosarcoma. In addition, there is no significant relationship between CRP and the prognosis of osteosarcoma from the point of Li et al. [13] and Liu et al. [10]. Hence, the association between systemic inflammatory marker (e.g., NLR, CRP, LMR, GPS, and PLR) levels and the overall survival of patients with osteosarcoma was explored by a meta-analysis, aiming to assess these biomarkers as prognostic factors for overall survival and disease-specific survival.

2. Methods

The registration of systematic inspection at PROSPERO (http://www.crd.york.ac.uk/PROSPERO) as CRD42021249954 was made on basis of the associated items of the PRISMA statement [14].

2.1. Search Strategy. The English literatures of PubMed, Embase, and Cochrane libraries and the Chinese literature of CNKI, Wanfang, and VIP from their establishment to April 2021 will be comprehensively and systematically searched. PubMed, Cochrane Library, and Embase were searched through the subject words and keywords retrieval method using the following keywords: “Osteosarcoma” [MeSH], “C-reactive protein” [MeSH], “neutrophil to lymphocyte ratio” [MeSH], “Glasgow prognostic score” [MeSH], “lymphocyte to monocyte ratio” [MeSH], and “platelet to lymphocyte ratio” [MeSH] (Supplementary File 1). The manual retrieval of other associated articles was made from the reference lists or citations in the primary search or applying “Similar Articles” PubMed option. The CNKI, Wanfang, and VIP were searched using the general Chinese translation of the above search terms: C-reactive protein (CRP), neutrophil to lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LMR), Glasgow prognostic score (GPS), and platelet to lymphocyte ratio (PLR).

2.2. Literature Inclusion and Exclusion Criteria. The eligibility criteria were mainly conducted in accordance with the PICOS (population, intervention/exposure, control, outcomes, and study design) principle limited to Chinese and English study.

The inclusion standards were shown below:

(a) Population. Patients with primary osteosarcoma who have survived radiation therapy, surgery, and chemotherapy
(b) Exposure. Risk factor (inflammatory marker), including NLR, CRP, GPS, PLR, and LMR level
(c) Comparators. Normal levels of inflammatory markers in normal subjects
(d) Outcomes. Survival outcomes or clinicopathological characteristics of osteosarcoma cases, such as recurrence and metastasis
(e) Study design. Case-control study or cohort study

The following exclusion criteria were utilized: (a) papers which were meta-analysis, reviews, animal experiments, case reports, conference abstracts, non-English/Chinese literature, mechanism researches or other diseases/cancers, or lacking the full text; (b) duplicate publication or overlapped data which was offered in the prior article; (c) study provided insufficient information on survival outcomes about HR, or no data presented for CRP, NLR, GPS, PLR, and LMR level.

2.3. Literature Screening and Data Extraction. Independently, all eligibility surveys for inclusion in the study were conducted by two authors (X.S. and H.Z.), and any differences that arose during the screening process were discussed, negotiated, and resolved by the two authors together. In case of questions or controversies, the decision was made after discussing or consulting with a third person (Y.H.). For the data extraction, the author, publication year, study area, research type, number of cases, follow-up, and hazard ratios (Table 1) are for evaluating neutrophil-to-lymphocyte ratio (NLR), Glasgow prognostic score (GPS), C-reactive protein (CRP), platelet to lymphocyte ratio (PLR), and lymphocyte–monocyte ratio (LMR) of overall survival (OS) and disease-specific survival (DPS).

2.4. Literature Quality Assessment. Two researchers (X.S. and F.Y.) separately made literature quality evaluations applying the Newcastle-Ottawa Scale (NOS) for cohort study [15] in Table 2. There are 4 items (4 points) for “Research Subject Selection,” 1 item (2 points) for “Comparability between Groups,” and 3 items (3 points) for “Result Measurement” in NOS, with a full score of 9 points and ≥7 is regarded as high-quality literature, less than 7 is classified as low-quality literature.

2.5. Data Synthesis and Statistical Analysis. STATA version 15.1 statistical software (StataCorp LP, College Station, TX) was used to analyze the data. The association of associated inflammatory factors with OS and DPS was evaluated by using hazard ratios (HR) and 95% confidence intervals (CI). Heterogeneity was assessed by Cochran’s Q statistic and I². If the heterogeneity test is $P \geq 0.1$ and $I^2 \leq 50\%$, indicating the existence of homogeneity among the studies, and the combined analysis was made by the fixed-effect model; if $P < 0.1$, $I^2 > 50\%$, it indicates whether there is heterogeneity in the study. The source of heterogeneity was found by
| Study                  | Year | Location | Sample size | Type                  | Metastasis | Follow-up* | Gender (m/f) | Treatment                                      | Outcomes | Inflammatory markers |
|------------------------|------|----------|-------------|-----------------------|------------|------------|--------------|------------------------------------------------|----------|---------------------|
| Funovics et al. [18]   | 2011 | Austria  | 79          | Osteosarcoma          | 30/49      | 33 (1-126) months | 42/37        | Chemotherapy; surgery                           | DPS/OS   | CRP                 |
| Nakamura et al. [19]   | 2013 | British  | 318         | Osteosarcoma; Ewing's sarcoma; chondrosarcoma | NO         | 40 (1-109) months | 176/142      | Radiotherapy; surgery; chemotherapy              | OS       | CRP                 |
| Liu et al. [20]        | 2015 | China    | 327         | Osteosarcoma          | 130/197    | 24 (3-60) months | 235/92       | Surgery; chemotherapy                           | OS       | LMR                 |
| Liu et al. [10]        | 2016 | China    | 162         | Osteosarcoma          | 78/162     | NA         | 96/66        | Chemotherapy; surgery                           | OS       | CRP, GPS, LMR, NLR, PLR |
| Aggerholm-Pedersen et al. [21] | 2016 | Denmark  | 172         | Chondrosarcoma; Ewing's sarcoma; osteosarcoma | NO         | 8.8 (4.3-19) years | 98/74        | Radiotherapy; surgery; chemotherapy              | DPS/OS   | CRP, GPS, NLR       |
| Xia et al. [11]        | 2016 | China    | 359         | Osteosarcoma          | 132/227    | 40 (3-60) months | 258/101      | Surgery; chemotherapy                           | OS       | NLR, PLR            |
| Li et al. [22]         | 2017 | China    | 215         | Osteosarcoma          | 30/49      | NA         | 122/94       | Surgery; chemotherapy                           | OS       | GPS, NLR, PLR       |
| Li et al. [13]         | 2015 | China    | 85          | Osteosarcoma          | 37/85      | NA         | 43/42        | Chemotherapy                                    | OS       | CRP                 |
| Jettoo et al. [23]     | 2019 | British  | 79          | Osteosarcoma; chondrosarcoma; Ewing's sarcoma | 14/63      | 45 (1-172) months | 44/35        | Surgery; chemotherapy                           | DPS/OS   | CRP                 |
| Huang et al. [24]      | 2018 | China    | 103         | Osteosarcoma          | 13/90      | 43 months | 63/40        | Surgery; chemotherapy                           | OS       | GPS, NLR            |
| Huang et al. [12]      | 2019 | China    | 126         | Osteosarcoma          | 7/119      | 44 (7-81) months | 78/48        | Surgery; chemotherapy                           | OS       | NLR, PLR            |
| Hu et al. [25]         | 2020 | China    | 137         | Osteosarcoma          | 61/76      | 55 (4-112) months | 80/57        | Surgery; chemotherapy                           | OS       | LMR                 |

Note: “*” median (minimum-maximum) follow-up time; NA: data were not provided in the publication.
Table 2: Newcastle-Ottawa scale (NOS) of cohort studies.

| Study                     | Year | Representativeness of exposed cohort | Selection of the nonexposed cohort | Ascertainment of exposure | Outcome of interest was not present | Comparability of exposure and nonexposure | Ascertainment of outcome | Follow-up enough for outcome | Adequacy of follow-up | Score |
|---------------------------|------|--------------------------------------|------------------------------------|---------------------------|-------------------------------------|-------------------------------------------|--------------------------|-----------------------------|------------------------|-------|
| Funovics et al. [18]      | 2011 | ★                                    | ★                                  | ★                         | ★                                   | ★                                         | ★                        | ★                          | ★                      | 7     |
| Hu et al. [25]            | 2020 | ★                                    | ★                                  | ★                         | ★                                   | ★                                         | ★                        | ★                          | ★                      | 8     |
| Huang et al. [12]         | 2019 | ★                                    | ★                                  | ★                         | ★                                   | ★                                         | ★                        | ★                          | ★                      | 8     |
| Jettoo et al. [23]        | 2019 | ★                                    | ★                                  | ★                         | ★                                   | ★                                         | ★                        | ★                          | ★                      | 8     |
| Aggerholm-Pedersen et al. [21] | 2016 | ★                                    | ★                                  | ★                         | ★                                   | ★                                         | ★                        | ★                          | ★                      | 7     |
| Li et al. [13]            | 2015 | ★                                    | ★                                  | ★                         | ★                                   | ★                                         | ★                        | ★                          | ★                      | 6     |
| Li et al. [22]            | 2017 | ★                                    | ★                                  | ★                         | ★                                   | ★                                         | ★                        | ★                          | ★                      | 8     |
| Liu et al. [10]           | 2016 | ★                                    | ★                                  | ★                         | ★                                   | ★                                         | ★                        | ★                          | ★                      | 8     |
| Liu et al. [20]           | 2015 | ★                                    | ★                                  | ★                         | ★                                   | ★                                         | ★                        | ★                          | ★                      | 7     |
| Nakamura et al. [19]      | 2013 | ★                                    | ★                                  | ★                         | ★                                   | ★                                         | ★                        | ★                          | ★                      | 7     |
| Xia et al. [11]           | 2016 | ★                                    | ★                                  | ★                         | ★                                   | ★                                         | ★                        | ★                          | ★                      | 8     |
| Huang et al. [24]         | 2018 | ★                                    | ★                                  | ★                         | ★                                   | ★                                         | ★                        | ★                          | ★                      | 7     |
3. Results

3.1. The Results of Literature Search. In this study, 593 studies were retrieved from the database in total. After eliminating duplicate studies, 97 were obtained. After browsing titles and abstracts, 36 researches were obtained. Finally, 12 articles meeting the requirements were brought into the meta-analysis (Figure 1), and there were 8 studies in China, 2 studies in British, 1 study in Denmark, and 1 study in Austria. The type of study included was a cohort study with a maximum follow-up time of 19 years (Table 1).

3.2. Systemic Inflammatory Markers and Overall Survival. 6 studies reported an association between C-reactive protein (CRP) and OS among patients with osteosarcoma. With a meta-analysis conducted through a random-effects model, the pooled results show that elevated CRP is significantly associated with shortening of OS in patients with osteosarcoma (HR = 1.68, 95% CI: 1.15-2.45, \( P = 0.007 \); \( I^2 = 84.7\% \), \( P < 0.0001 \); Figure 2(a)).

6 studies reported an association between monocyte ratio (LMR) and OS among patients with osteosarcoma. With a meta-analysis conducted through a random-effects model, the pooled results show that there is no significantly associated with shortening of OS in patients with osteosarcoma (HR = 1.96, 95% CI: 1.28-3.00, \( P = 0.002 \); \( I^2 = 60.0\% \), \( P = 0.028 \); Figure 2(b)).

3 studies reported an association between lymphocyte-monocyte ratio (LMR) and OS among patients with osteosarcoma. With a meta-analysis conducted through a random-effects model, the pooled results show that there is no significantly associated with shortening of OS among patients with osteosarcoma (HR = 0.60, 95% CI: 0.30-1.18, \( P = 0.138 \); \( I^2 = 82.7\% \), \( P = 0.003 \); Figure 2(c)).

4 studies reported an association between Glasgow prognostic score (GPS) and OS among patients with osteosarcoma. With a meta-analysis conducted through a fixed-effects model, the pooled results show that GPS is significantly associated with shortening of OS among patients suffering from osteosarcoma (HR = 2.54, 95% CI: 1.95-3.31, \( P < 0.0001 \); \( I^2 = 0.0\% \), \( P = 0.496 \); Figure 2(d)).

4 studies reported an association between platelet to lymphocyte ratio (PLR) and OS among patients with osteosarcoma. A meta-analysis was conducted through a random-effects model, and the pooled results show that there is no significant relationship between PLR and OS of patients with osteosarcoma.
| Study ID                      | HR (95% CI)        | % Weight |
|------------------------------|--------------------|----------|
| Aggerholm-Pedersen et al. (2016) | 2.20 (1.00, 5.20)  | 10.75    |
| Liu et al. (2016)            | 2.10 (1.20, 3.66)  | 14.95    |
| Xia et al. (2016)            | 1.80 (1.35, 2.41)  | 19.65    |
| Li et al. (2017)             | 1.81 (1.23, 2.67)  | 17.99    |
| Huang et al. (2018)          | 2.06 (1.18, 3.60)  | 14.91    |
| Huang et al. (2019)          | 0.98 (0.88, 1.13)  | 21.75    |
| Overall ($I^2 = 84.7\%, P = 0.000$) | 1.68 (1.15, 2.45)  | 100.00   |

Note: Weights are from random effects analysis

---

| Study ID                      | HR (95% CI)        | % Weight |
|------------------------------|--------------------|----------|
| Funovics et al. (2011)       | 1.40 (1.00, 1.80)  | 28.40    |
| Nakamura et al. (2013)       | 1.67 (1.12, 3.00)  | 22.77    |
| Li et al. (2015)             | 2.39 (0.22, 4.67)  | 6.24     |
| Aggerholm-Pedersen et al. (2016) | 3.60 (2.10, 6.30)  | 21.19    |
| Liu et al. (2016)            | 1.17 (0.52, 2.61)  | 15.04    |
| Jettoo et al. (2019)         | 5.95 (1.30, 26.66) | 6.36     |
| Overall ($I^2 = 60.0\%, P = 0.028$) | 1.96 (1.28, 3.00)  | 100.00   |

Note: Weights are from random effects analysis

---

| Study ID                      | HR (95% CI)        | % Weight |
|------------------------------|--------------------|----------|
| Liu et al. (2015)            | 0.34 (0.24, 0.46)  | 37.28    |
| Liu et al. (2016)            | 0.93 (0.52, 1.64)  | 31.69    |
| Hu et al. (2020)             | 0.75 (0.41, 1.36)  | 31.03    |
| Overall ($I^2 = 82.7\%, P = 0.003$) | 0.60 (0.30, 1.18)  | 100.00   |

Note: Weights are from random effects analysis

---

Figure 2: Continued.
osteosarcoma (HR = 1.13, 95% CI: 0.85-1.49, P = 0.405; \(I^2 = 69.8\%\), P = 0.003; Figure 2(e)).

3.3. Systemic Inflammatory Markers and Disease-Specific Survival. There were 3 studies that reported the relationship between C-reactive protein level and disease-specific survival (DPS). Additionally, the pooled results show that CRP is greatly related to the shortening of DPS among patients suffering from osteosarcoma (HR = 2.76, 95% CI: 2.01-3.80, P < 0.0001; \(I^2 = 0.0\%\), P = 0.549; Figure 3).

3.4. Subgroup Analysis for Neutrophil-to-Lymphocyte Ratio. For the detection of the potential source of heterogeneity in analyzing the relation between NLR and OS, ethnicity, metastasis, histology, and sample size were applied to stratify the subgroup analysis. The pooled results show that the elevated NLR predicts poorer OS in Asian populations (HR = 1.63, 95% CI: 1.09-2.43, P = 0.017; Figure 4(a)), while the relationship between the level of NLR and OS was not significant in European populations (HR = 2.20, 95% CI: 0.96-5.02, P = 0.067; Figure 4(a)).

Subgroup analyses were also performed on histology and metastasis to further explain. Among patients suffering from osteosarcoma, growing NLR was related to shortened OS (HR = 1.63, 95% CI: 1.09-2.43, P = 0.017; Figure 4(b)). However, according to the pooled outcomes, there is no great relation between NLR and OS of patients suffering from osteosarcoma and other bone cancers (HR = 2.20, 95% CI: 0.96-5.02, P = 0.061; Figure 4(b)).

An enhanced level of NLR was related to reduced survival among patients with metastasis (HR = 1.63, 95% CI: 1.09-2.43, P = 0.017; Figure 4(c)), while the association between the level of NLR and OS was not evident in patients without metastasis (HR = 2.20, 95% CI: 0.96-5.02, P = 0.061; Figure 4(c)).

3.5. Subgroup Analysis for C-Reactive Protein. Subgroup analysis for the detection of the potential source of
heterogeneity in analyzing the association between CRP and OS was made by stratification by ethnicity, histology, metastasis, and sample size. The pooled results show that poorer OS in European populations (HR = 2.19, 95% CI: 1.28-3.74, P = 0.004; Figure 5(a)) can be predicted by the enhanced CRP level, while there was no great relationship between the level of CRP and OS in Asian populations (HR = 1.36, 95% CI: 0.67-2.78, P = 0.394; Figure 5(a)). Subgroup analyses on metastasis, histology, and sample size were performed for further explanation to further explain. Among patients suffering from osteosarcoma, increased CRP level was correlated with shortened OS (HR = 1.39, 95% CI: 1.06-1.83, P = 0.016; Figure 5(b)), and patients with bone sarcomas encountered the same situation (HR = 2.78; 95% CI: 1.40-5.49, P = 0.003; Figure 5(b)). An enhanced level of CRP was related to reduced survival among patients with or without metastasis (Figure 5(c)). Additionally, the pooled outcomes displayed that in studies with a sample size of greater than or equal to 100 patients, elevated CRP predicted poor OS (HR = 1.99, 95% CI: 1.06-3.74, P = 0.032; Figure 5(d)). However, in a sample size less than 100, relationship between CRP and OS was not significant (HR = 2.10, 95% CI: 0.92-4.81, P = 0.080; Figure 5(d)).

3.6. Sensitivity Analysis. Sensitivity analysis eliminated every included research successively and performed a summary discussion on the remaining researches to evaluate whether a single included research excessively influenced on the overall outcomes of the meta-analysis. The outcomes of the sensitivity analysis are shown in Supplementary file 2, indicating that no research exerted an excessive impact on the outcomes of the meta-analysis, and that the outcomes of the remaining researches are stable and credible.

3.7. Publication Bias. The Begg’s funnel plot of this study is shown in Supplementary file 3. It could be seen that the funnel plot was basically symmetrical, and the P value of Egger’s test for NLR was 0.115 (Figure 6), for CRP was 0.762, for GPS was 0.130, indicating that no obvious publication bias in this study.

4. Discussion

This meta-analysis pooled 12 researches, including 2,162 patients, to examine the relation between C-reactive protein (CRP), neutrophil to lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LPR), Glasgow prognostic score (GPS), and platelet to lymphocyte ratio (PLR) levels with the OS of patients suffering from osteosarcoma, aiming to assess these biomarkers as prognostic elements for overall survival and disease-specific survival.

Inflammation is essential for human tumors, malignant transformation, and antitumor immunity [26]. It is increasingly recognized that systemic inflammation exerts a vital effect on the occurrence and growth of cancer [27, 28]. Inflammatory factors can directly provide free radicals to attack normal DNA mechanisms and cause cancer or indirectly damage DNA and regulate gene expression by affecting the epigenetic characteristics of cells [29]. Neoplastic cells often excessively express proinflammatory mediators such as proteases, cytokines, and chemokines [30]. Various types of oncogenes are activated through mutation, chromosomal rearrangement, or amplification. Transformed cells undergoing this process produce inflammatory mediators that activate the expression of transcription factors. Then, activated transcription factors further coordinate the production of inflammatory mediators and ultimately form cancer-related microenvironments [27]. It is not surprising to detect increased levels of CRP, NLR, or GPS in cancer because of the importance of the inflammation in the development of cancer.

It is known that NLR values increase in acute pancreatitis [31], cardiac events [32], and atherosclerosis [33]. As a marker of systemic inflammation, NLR can also be considered as a potential prognostic factor for different tumors. Pretreatment NLR was utilized as a prognostic indicator of long-term mortality in patients with breast cancer by Azab

| Study ID | HR (95% CI) | % Weight |
|----------|-------------|----------|
| Funovics et al. (2011) | 2.11 (0.75, 5.95) | 9.45 |
| Nakamura et al. (2013) | 2.54 (1.69, 3.81) | 61.36 |
| Aggerholm-Pedersen et al. (2016) | 3.60 (2.00, 6.50) | 29.19 |
| Overall (I² = 0.0%, P = 0.549) | 2.76 (2.01, 3.80) | 100.00 |

Figure 3: The association of CRP levels with the disease-specific survival of patients with osteosarcoma.
| Study ID                              | HR (95% CI) | % Weight |
|--------------------------------------|-------------|----------|
| European                             |             |          |
| Aggerholm-Pedersen et al. (2016)     | 2.20 (1.00, 5.20) | 10.75    |
| Subtotal \((I^2 = .\%, \ P = .)\)   | 2.20 (0.96, 5.02) | 10.75    |
| Asian                                |             |          |
| Liu et al. (2016)                    | 2.10 (1.20, 3.66) | 14.95    |
| Xia et al. (2016)                    | 1.80 (1.35, 2.41) | 19.65    |
| Li et al. (2017)                     | 1.81 (1.23, 2.67) | 17.99    |
| Huang et al. (2018)                  | 2.06 (1.18, 3.60) | 14.91    |
| Huang et al. (2019)                  | 0.98 (0.88, 1.13) | 21.75    |
| Subtotal \((I^2 = 86.8\%, \ P = 0.000)\) | 1.63 (1.09, 2.43) | 89.25    |
| Overall \((I^2 = 84.7\%, \ P = 0.000)\) | 1.68 (1.15, 2.45) | 100.00   |

Note: Weights are from random effects analysis

| Study ID                              | HR (95% CI) | % Weight |
|--------------------------------------|-------------|----------|
| Osteosarcoma and other               |             |          |
| Aggerholm-Pedersen et al. (2016)     | 2.20 (1.00, 5.20) | 10.75    |
| Subtotal \((I^2 = .\%, \ P = .)\)   | 2.20 (0.96, 5.02) | 10.75    |
| osteosarcoma                         |             |          |
| Liu et al. (2016)                    | 2.10 (1.20, 3.66) | 14.95    |
| Xia et al. (2016)                    | 1.80 (1.35, 2.41) | 19.65    |
| Li et al. (2017)                     | 1.81 (1.23, 2.67) | 17.99    |
| Huang et al. (2018)                  | 2.06 (1.18, 3.60) | 14.91    |
| Huang et al. (2019)                  | 0.98 (0.88, 1.13) | 21.75    |
| Subtotal \((I^2 = 86.8\%, \ P = 0.000)\) | 1.63 (1.09, 2.43) | 89.25    |
| Overall \((I^2 = 84.7\%, \ P = 0.000)\) | 1.68 (1.15, 2.45) | 100.00   |

Note: Weights are from random effects analysis

Figure 4: Continued.
et al. [34]. According to Deng et al., preoperative NLR is a separate prognostic factor specific to cancer survival among patients undergoing gastric cancer surgery [9]. However, the relation between NLR and the prognosis of patients suffering from osteosarcoma remains controversial. The pooled outcomes showed that enhanced NLR is greatly related to the shortening of OS in patients with osteosarcoma, showing that great serum levels of NLR before treatment may be a negative prognostic element for patients suffering from bone cancers.

It has been also shown that increased levels of systemic inflammation are related to lower survival rates in patients with solid tumors [35, 36]. CRP is a nonspecific but sensitive marker of systemic inflammation synthesized by liver cells replying microbial invasion or tissue damage [37]. It is well known that during inflammation, acute infection, and tissue damage, CRP levels will rise rapidly. In addition, enhanced CRP levels are also regarded as a significant risk element for atherosclerosis [38], stroke [39–41], and myocardial infarction [42]. Importantly, it has been confirmed that the preoperative level of serum CRP is related to the prognosis of hepatocellular carcinoma [43] and pancreatic cancer [44]. Our pooled results also found that elevated levels of CRP are greatly related to the shortening of OS in patients with osteosarcoma (HR = 1.96, 95% CI: 1.28-3.00) which conforms to the outcomes of most researches [13, 18, 19, 21]. Additionally, pooled result showed that CRP is significantly associated with shortening of DPS in patients with osteosarcoma (HR = 2.76, 95% CI: 2.01-3.80). These all suggested that CRP is a risk factor for the prognosis of osteosarcoma. To improve the prognosis of the patients with elevated CRP, NLR, and GPS, it is urgently needed a management protocol for systemic inflammatory response via the tumor-host interaction during the postoperative course is urgently needed to improve their prognosis [45].

Simultaneously, no great association between the level of NLR and OS in Europe patients was found in the stratified analysis (HR = 2.20, 95% CI: 1.00-5.20) and no significant association between CRP levels and OS in Asia patients (HR = 1.36, 95% CI: 0.67-2.78). This may be due to the differences in the susceptibility genes, treatment options, and CRP measurement methods of bone tumors in Asia and Europe. Subgroup analyses on metastasis, histology, and sample size were made for the explanation of heterogeneity. In the analysis of NLR, the pooled results showed that there is no significant relationship between NLR and OS of patients suffering from osteosarcoma and other bone cancers (HR = 2.20, 95% CI: 1.00-5.20). The similar result also appeared in nonmetastasis osteosarcoma, indicating that histology and metastasis may be the cause of high heterogeneity. In the analysis of CRP, enhanced CRP was related to shortened OS in patients with osteosarcoma (HR = 1.39, 95% CI: 1.06-1.83), and patients with other bone cancers encountered the same situation. Similarly, the pooled results showed that an enhanced level of CRP was related to reduced OS in patients with osteosarcoma regardless of metastasis. The results suggested that this high heterogeneity may be independent of histology and metastasis.

| Study ID | HR (95% CI) | % Weight |
|----------|------------|----------|
| No       |            |          |
| Aggerholm-Pedersen et al. (2016) | 2.20 (1.00, 5.20) | 10.75 |
| Subtotal (I² = .%, P = .) | 2.20 (0.96, 5.02) | 10.75 |
| Yes      |            |          |
| Liu et al. (2016) | 2.10 (1.20, 3.66) | 14.95 |
| Xia et al. (2016) | 1.80 (1.35, 2.41) | 19.65 |
| Li et al. (2017) | 1.81 (1.23, 2.67) | 17.99 |
| Huang et al. (2018) | 2.06 (1.18, 3.60) | 14.91 |
| Huang et al. (2019) | 0.98 (0.88, 1.13) | 21.75 |
| Subtotal (I² = 86.8%, P = 0.000) | 1.63 (1.09, 2.43) | 89.25 |
| Overall (I² = 84.7%, P = 0.000) | 1.68 (1.15, 2.45) | 100.00 |

Note: Weights are from random effects analysis

Figure 4: Subgroup analysis of the association of NLR levels with the OS of patients with osteosarcoma. The association of overall survival within European or Asian patients (a), osteosarcoma or other bone sarcomas (b), metastasis or nonmetastasis patients (c), and NLR levels with the OS of patients with osteosarcoma.
| Study ID                  | HR (95% CI)       | % Weight |
|--------------------------|-------------------|----------|
| **European**             |                   |          |
| Funovics et al. (2011)   | 1.40 (1.00, 1.80) | 28.40    |
| Nakamura et al. (2013)   | 1.67 (1.12, 3.00) | 22.77    |
| Aggerholm-Pedersen et al. (2016) | 3.60 (2.10, 6.30) | 21.19    |
| Jetto et al. (2019)      | 5.95 (1.30, 26.66)| 6.36     |
| Subtotal ($I^2 = 73.7\%$, $P = 0.010$) | 2.19 (1.28, 3.74) | 78.72    |
| **Asian**                |                   |          |
| Li et al. (2015)         | 2.39 (0.22, 4.67) | 6.24     |
| Liu et al. (2016)        | 1.17 (0.52, 2.61) | 15.04    |
| Subtotal ($I^2 = 0.0\%$, $P = 0.415$) | 1.36 (0.67, 2.78) | 21.28    |
| Overall ($I^2 = 60.0\%$, $P = 0.028$) | 1.96 (1.28, 3.00) | 100.00   |
| **Mediators of Inflammation** |               |          |
| Study ID                  | HR (95% CI)       | % Weight |
|--------------------------|-------------------|----------|
| **Osteosarcoma**         |                   |          |
| Funovics et al. (2011)   | 1.40 (1.00, 1.80) | 28.40    |
| Li et al. (2015)         | 2.39 (0.22, 4.67) | 6.24     |
| Liu et al. (2016)        | 1.17 (0.52, 2.61)| 15.04    |
| Subtotal ($I^2 = 0.0\%$, $P = 0.716$) | 1.39 (1.06, 1.83) | 49.68    |
| **Osteosarcoma and other** |                 |          |
| Nakamura et al. (2013)   | 1.67 (1.12, 3.00) | 22.77    |
| Aggerholm-Pedersen et al. (2016) | 3.60 (2.10, 6.30) | 21.19    |
| Jetto et al. (2019)      | 5.95 (1.30, 26.66)| 6.36     |
| Subtotal ($I^2 = 63.9\%$, $P = 0.063$) | 2.78 (1.40, 5.49) | 50.32    |
| Overall ($I^2 = 60.0\%$, $P = 0.028$) | 1.96 (1.28, 3.00) | 100.00   |

Note: Weights are from random effects analysis

Figure 5: Continued.
The definition of GPS was carried out on the basis of the presence of hypoalbuminemia (<35 g/L) and enhanced CRP (>10 mg/L): if both were abnormal, the score was 2; if either was abnormal, the score was 1; if there were no exceptions, the score was 0 [46, 47]. According to increasing researches, the hidden predictive value of GPS was demonstrated among osteosarcoma patients. One study speculates that GPS shows inflammation status and nutritional status of cancer patients as a better predictor of prognosing cancer than CRP [10]. Hence, this systematic examination and

| Study ID                  | HR (95% CI)  | % Weight |
|---------------------------|--------------|----------|
| Yes                       |              |          |
| Funovics et al. (2011)    | 1.40 (1.00, 1.80) | 28.40    |
| Li et al. (2015)          | 2.39 (0.22, 4.67) | 6.24     |
| Liu et al. (2016)         | 1.17 (0.52, 2.61) | 15.04    |
| Jettoo et al. (2019)      | 5.95 (1.30, 26.66) | 6.36     |
| Subtotal ($I^2 = 26.9\%, P = 0.251$) | 1.58 (1.00, 2.50) | 56.03 |
| No                        |              |          |
| Nakamura et al. (2013)    | 1.67 (1.12, 3.00) | 22.77    |
| Aggerholm-Pedersen et al. (2016) | 3.60 (2.10, 6.30) | 21.19    |
| Subtotal ($I^2 = 76.0\%, P = 0.041$) | 2.43 (1.14, 5.15) | 43.97    |
| Overall ($I^2 = 60.0\%, P = 0.028$) | 1.96 (1.28, 3.00) | 100.00    |

Note: Weights are from random effects analysis

| Study ID                  | HR (95% CI)  | % Weight |
|---------------------------|--------------|----------|
| <100                      |              |          |
| Funovics et al. (2011)    | 1.40 (1.00, 1.80) | 28.40    |
| Li et al. (2015)          | 2.39 (0.22, 4.67) | 6.24     |
| Jettoo et al. (2019)      | 5.95 (1.30, 26.66) | 6.36     |
| Subtotal ($I^2 = 46.9\%, P = 0.152$) | 2.10 (0.92, 4.81) | 41.00    |
| ≥100                      |              |          |
| Nakamura et al. (2013)    | 1.67 (1.12, 3.00) | 22.77    |
| Aggerholm-Pedersen et al. (2016) | 3.60 (2.10, 6.30) | 21.19    |
| Liu et al. (2016)         | 1.17 (0.52, 2.61) | 15.04    |
| Subtotal ($I^2 = 69.6\%, P = 0.037$) | 1.99 (1.06, 3.74) | 59.00    |
| Overall ($I^2 = 60.0\%, P = 0.028$) | 1.96 (1.28, 3.00) | 100.00 |

Note: Weights are from random effects analysis

Figure 5: Subgroup analysis of the association of CRP levels with the OS of patients with osteosarcoma. The association of CRP level and overall survival within European or Asian patients (a), osteosarcoma or other bone sarcomas (b), metastasis or nonmetastasis patients (c), sample size (d) in patients with osteosarcoma.
Figure 6: Egger’s test of the association of NLR (a), CRP (b), and GPS (c) levels with the OS of patients with osteosarcoma.
meta-analysis shall be made to draw more reliable conclusions on the effect of GPS on osteosarcoma. In this meta-analysis, measuring GPS was an effective way to predict prognosis among patients suffering from osteosarcoma. Additionally, according to the pooled results, GPS is significantly associated with shortening of OS in patients with osteosarcoma (HR = 2.54, 95% CI: 1.95-3.31), demonstrating that high level of GPS before treatment may also be a negative prognostic element for patients with osteosarcoma.

The prognostic value of PLR and LMR for other tumors shows different conclusions from this article. In the latest study, PLR is thought to be inversely associated with the prognosis of breast cancer [48], and LMR is considered as a risk factor for gastric cancer [49]. The pooled results show that there is no significant relationship between PLR or LMR and OS of patients with osteosarcoma. This anomaly of LMR may be related to the insufficient number of included studies; in addition to this, there remains a study for PLR showing that the predictive value of high PLR in terms of overall survival is greater in cancer patients with comorbidities, especially those with metabolic syndrome [50] which may not be consistent with patients with osteosarcoma. In addition, due to the error of measurement results and the influence of other unrelated confounding factors, some research results may be ignored and reported, resulting in the trend of the prognostic value of these two inflammatory markers for osteosarcoma is not obvious. However, specific conclusions need to be supported by further research results.

Different types of treatment and osteosarcoma may have different overall survival times, which may contribute to high heterogeneity. Due to the differences between individuals and groups, patients of different races, regions, and ages may have different degrees of disease or disease tendency, resulting in different treatment methods. This leads to the blending of various factors, which we cannot distinguish in detail for the time being. We believe that there will be more scientific statistical methods and more rigorous experimental design to solve these problems in the future.

In addition to the above problems, this meta-analysis does have several limitations. First, most of the included studies were retrospectively designed, which increased the risk of bias due to inadequate random blinding. Second, even though subgroup analyses were performed, there was an obvious heterogeneity in this meta-analysis, but at present, we have not yet found a clear cause for the heterogeneity. Third, the overall results may be overestimated because of negative data from unpublished studies. Fourth, restricted by insufficient number of literature and the original data, the reliability of the results may be shortened and we cannot draw receiver operating characteristic curves (ROC curves) to study the prognostic value of each marker, further. We can only expect more studies to be carried out so that we can update this meta-analysis. Finally, sensitivity analysis and funnel plots showed potential publication bias in some researches. After ignoring these researches, the distribution of OS in the remaining studies was more symmetrical. This bias may be due to differences in baseline characteristics and study regimen-related protocols among patients. Moreover, the differences in detection methods and data storage may have resulted in heterogeneity. Although the random effects model reduced the effect of heterogeneity, the heterogeneity between studies was not abolished. In view of the above limitations, it is recommended to prospectively recruit subjects in future studies. At the same time, researchers may consider combining multiple inflammatory markers to explore their common prognostic value and make the results more sensitive.

5. Conclusion

For patients with osteosarcoma, meta-analysis performed in this paper demonstrated that high great contents of NLR, CRP, and GPS before treatment may be a negative prognostic element, and ethnicity, histology, and metastasis all have an impact on its prognosis of patients with osteosarcoma; however, PLR and LMR might have nothing to do with it. In conclusion, the measurement of these inflammatory markers’ levels can provide the basis for clinicians to judge the outcome of prognosis.

Data Availability

The datasets are available from the corresponding author on reasonable request.

Additional Points

Code Availability. Microsoft Excel 2010; Microsoft, Redmond, WA, USA. STATA meta. Ado module (version 15.1; College Station, TX, USA).

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

Xiaotong Song and Hao Zhang wrote the manuscript; Yanshuo Han and Xiaotong Song conceived the manuscript; Xiaotong Song, Jinzhu Liu, and Yanshuo Han participated in data collection; all authors have read and approved the final manuscript. Xiaotong Song and Hao Zhang are co-first authors in this study and they contributed equally to this work.

Acknowledgments

This work was supported by the Fundamental Research Funds for the Central Universities (grant number: DUT19RC(3)076), the National Natural Science Foundation of China (grant number: 81600370), and the China Postdoctoral Science Foundation (grant number: 2018M640270).

Supplementary Materials

Supplementary File 1: search strategy for Medline database.
Supplementary File 2: sensitivity analysis of the association of NLR, CRP, LMR, GRS, and PLR levels with the OS of patients with osteosarcoma. Supplementary File 3: Begg’s
funnel plot of the association of NLR, CRP, and GPS levels with the OS of patients with osteosarcoma. (Supplementary Materials)

References

[1] L. Mirabello, R. J. Troisi, and S. A. Savage, “Osteosarcoma incidence and survival rates from 1973 to 2004,” Cancer, vol. 115, no. 7, pp. 1531–1543, 2009.

[2] I. Lilental and N. Herold, “Targeting molecular mechanisms underlying treatment efficacy and resistance in osteosarcoma: a review of current and future strategies,” International Journal of Molecular Sciences, vol. 21, no. 18, p. 6885, 2020.

[3] C. A. Stillier, “International patterns of cancer incidence in adolescents,” Cancer Treatment Reviews, vol. 33, no. 7, pp. 631–645, 2007.

[4] S. S. Nathan and J. H. Healey, “Demographic determinants of survival in osteosarcoma,” Annals of the Academy of Medicine, Singapore, vol. 41, no. 9, pp. 390–399, 2012.

[5] Y. J. Li, Y. L. Dai, Y. S. Cheng, W. B. Zhang, and C. Q. Tu, “Positron emission tomography (18)F-fluorodeoxyglucose uptake and prognosis in patients with bone and soft tissue sarcoma: a meta-analysis,” European Journal of Surgical Oncology, vol. 42, no. 8, pp. 1103–1114, 2016.

[6] K. J. Halazun, A. Aldoori, H. Z. Malik et al., “Elevated preoperative neutrophil to lymphocyte ratio predicts survival following hepatic resection for colorectal liver metastases,” European Journal of Surgical Oncology, vol. 34, no. 1, pp. 55–60, 2008.

[7] P. I. Karakiewicz, G. C. Hutterer, Q. D. Trinh et al., “C-reactive protein is an informative predictor of renal cell carcinoma-specific mortality,” Cancer, vol. 110, no. 6, pp. 1241–1247, 2007.

[8] L. M. Forrest, D. C. McMillan, C. S. McArdle, W. J. Angerson, K. Dagg, and H. R. Scott, “A prospective longitudinal study of performance status, an inflammation-based score (GPS) and survival in patients with inoperable non-small-cell lung cancer,” British Journal of Cancer, vol. 92, no. 10, pp. 1834–1836, 2005.

[9] Q. Deng, B. He, X. Liu et al., “Prognostic value of pre-operative inflammatory response biomarkers in gastric cancer patients and the construction of a predictive model,” Journal of Translational Medicine, vol. 13, no. 1, p. 66, 2015.

[10] B. Liu, Y. Huang, Y. Sun et al., “Prognostic value of inflammation-based scores in patients with osteosarcoma,” Scientific Reports, vol. 6, no. 1, p. 39862, 2016.

[11] W. K. Xia, Z. L. Liu, D. Shen, Q. F. Lin, J. Su, and W. D. Mao, “Prognostic performance of pre-treatment NLR and PLR in patients suffering from osteosarcoma,” World Journal of Surgical Oncology, vol. 14, no. 1, 2016.

[12] X. Huang, H. Hu, W. Zhang, and Z. Shao, “Prognostic value of prognostic nutritional index and systemic immune-inflammation index in patients with osteosarcoma,” Journal of Cellular Physiology, vol. 234, no. 10, pp. 18408–18414, 2019.

[13] X. Li, F. Tian, F. Wang, and Y. Li, “Serum C-reactive protein and overall survival of patients with osteosarcoma,” Tumor Biology, vol. 36, no. 7, pp. 5663–5666, 2015.

[14] D. Moher, A. Liberati, J. Tetzlaff, D. G. Altman, and The PRISMA Group, “Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement,” PLoS Medicine, vol. 6, no. 7, article e1000097, 2009.

[15] D. A. Cook and D. A. Reed, “Appraising the quality of medical education research methods,” Academic Medicine, vol. 90, no. 8, pp. 1067–1076, 2015.

[16] C. B. Begg and M. Mazumdar, “Operating characteristics of a rank correlation test for publication bias,” Biometrics, vol. 50, no. 4, pp. 1088–1101, 1994.

[17] M. Borenstein, L. V. Hedges, J. P. Higgins, and H. R. Rothstein, “A basic introduction to fixed-effect and random-effects models for meta-analysis,” Research Synthesis Methods, vol. 1, no. 2, pp. 97–111, 2010.

[18] P. T. Funovics, G. Edelhauser, M. A. Funovics et al., “Pre-operative serum C-reactive protein as independent prognostic factor for survival but not infection in patients with high-grade osteosarcoma,” International Orthopaedics, vol. 35, no. 10, pp. 1529–1536, 2011.

[19] T. Nakamura, R. J. Grimer, C. L. Gaston, M. Watanuki, A. Sudo, and L. Jey, “The prognostic value of the serum level of C-reactive protein for the survival of patients with a primary sarcoma of bone,” Bone Joint J, vol. 95-b, no. 3, pp. 411–418, 2013.

[20] T. Liu, X. C. Fang, Z. Ding, Z. G. Sun, L. M. Sun, and Y. L. Wang, “Pre-operative lymphocyte-to-monocyte ratio as a predictor of overall survival in patients suffering from osteosarcoma,” FEBS Open Bio, vol. 5, no. 1, pp. 682–687, 2015.

[21] N. Aggerholm-Pedersen, K. Maretty-Kongstad, J. Keller, S. Baerentzen, and A. Safwat, “The prognostic value of serum biomarkers in localized bone sarcoma,” Translational Oncology, vol. 9, no. 4, pp. 322–328, 2016.

[22] Y. J. Li, K. Yao, M. X. Lu, W. B. Zhang, C. Xiao, and C. Q. Tu, “Prognostic value of the C-reactive protein to albumin ratio: a novel inflammation-based prognostic indicator in osteosarcoma,” Oncotargets and Therapy, vol. Volume 10, pp. 5255–5261, 2017.

[23] P. Jettoo, G. J. S. Tan, C. H. Gerrand, and K. S. Rankin, “Role of routine blood tests for predicting clinical outcomes in osteosarcoma patients,” Journal of Orthopaedic Surgery, vol. 27, no. 2, p. 230949901983829, 2019.

[24] H. Zhenhua, Y. Chen, L. Yuling, D. Qiong, and R. Xiaoxiang, “Role of systemic inflammatory response in evaluating the prognosis of patients with osteosarcoma,” The Journal of Practical Medicine, vol. 34, no. 20, pp. 3410–3414, 2018.

[25] H. Hu, X. Deng, Q. Song et al., “Prognostic value of the preoperative lymphocyte-to-c-reactive protein ratio and albumin-to-globulin ratio in patients with osteosarcoma,” Oncotargets and Therapy, vol. Volume 13, pp. 12673–12681, 2020.

[26] M. L. Pot, J. C. Giltay, A. van Wijzen, and E. J. Breslau-Siderius, “Unbalanced karyotype, dup 14(q13-q22), in a mother and her two children,” Clinical Genetics, vol. 50, no. 5, pp. 398–402, 1996.

[27] A. Mantovani, P. Allavena, A. Sic, and F. Balkwill, “Cancer-related inflammation,” Nature, vol. 454, no. 7203, pp. 436–444, 2008.

[28] C. L. Diakos, K. A. Charles, D. C. McMillan, and S. J. Clarke, “Cancer-related inflammation and treatment effectiveness,” The Lancet Oncology, vol. 15, no. 11, pp. e493–e503, 2014.

[29] E. Elinav, R. Nowarski, C. A. Thaiss, B. Hu, C. Jin, and R. A. Flavell, “Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms,” Nature Reviews. Cancer, vol. 13, no. 11, pp. 759–771, 2013.
[30] J. Candido and T. Hagemann, “Cancer-related inflammation,” *Journal of Clinical Immunology*, vol. 33, no. 1, pp. S79–S84, 2013.

[31] B. Azab, N. Jaglall, J. P. Atallah et al., “Neutrophil-lymphocyte ratio as a predictor of adverse outcomes of acute pancreatitis,” *Pancreatology*, vol. 11, no. 4, pp. 445–452, 2011.

[32] A. C. Sawant, P. Adhikari, S. R. Narra, S. S. Srivatsa, P. K. Mills, and S. S. Srivatsa, “Neutrophil to lymphocyte ratio predicts short- and long-term mortality following revascularization therapy for ST elevation myocardial infarction,” *Cardiology Journal*, vol. 21, no. 1, pp. 500–508, 2014.

[33] O. F. Cirakoglu and A. S. Yilmaz, “Systemic immune-inflammation index is associated with increased carotid intima-media thickness in hypertensive patients,” *Clinical and Experimental Hypertension*, vol. 43, no. 6, pp. 565–571, 2021.

[34] B. Azab, N. Shah, J. Radbel et al., “Pretreatment neutrophil/lymphocyte ratio is superior to platelet/lymphocyte ratio as a predictor of long-term mortality in breast cancer patients,” *Medical Oncology*, vol. 30, no. 1, p. 432, 2013.

[35] M. J. Proctor, D. S. Morrison, D. Talwar et al., “A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study,” *European Journal of Cancer*, vol. 47, no. 17, pp. 2633–2641, 2011.

[36] C. S. Roxburgh and D. C. McMillan, “Role of systemic inflammatory response in predicting survival in patients with primary operable cancer,” *Future Oncology*, vol. 6, no. 1, pp. 149–163, 2010.

[37] G. Morris-Stiff, D. Gomez, and K. R. Prasad, “C-reactive protein in liver cancer surgery,” *European Journal of Surgical Oncology*, vol. 34, no. 7, pp. 727–729, 2008.

[38] P. Libby, P. M. Ridker, and A. Maseri, “Inflammation and atherosclerosis,” *Circulation*, vol. 105, no. 9, pp. 1135–1143, 2002.

[39] N. S. Rost, P. A. Wolf, C. S. Kase et al., “Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham study,” *Stroke*, vol. 32, no. 11, pp. 2575–2579, 2001.

[40] K. W. Muir, C. J. Weir, W. Alwan, I. B. Squire, and K. R. Lees, “C-reactive protein and outcome after ischemic stroke,” *Stroke*, vol. 30, no. 5, pp. 981–985, 1999.

[41] F. Zhou, L. Zhou, T. Guo et al., “Plasma proteomics reveals coagulation, inflammation, and metabolic shifts in H-type hypertension patients with and without acute ischemic stroke,” *OncoTarget*, vol. 8, no. 59, pp. 100384–100395, 2017.

[42] P. M. Ridker, R. J. Glynn, and C. H. Hennekens, “C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction,” *Circulation*, vol. 97, no. 20, pp. 2007–2011, 1998.

[43] K. Hashimoto, Y. Ikeda, D. Korenaga et al., “The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma,” *Cancer*, vol. 103, no. 9, pp. 1856–1864, 2005.

[44] J. Szkandera, M. Stotz, G. Absenger et al., “Validation of C-reactive protein levels as a prognostic indicator for survival in a large cohort of pancreatic cancer patients,” *British Journal of Cancer*, vol. 110, no. 1, pp. 183–188, 2014.

[45] Y. Okugawa, Y. Shirai, Y. Toiyama et al., “Clinical burden of modified Glasgow prognostic scale in colorectal cancer,” *Anticancer Research*, vol. 38, no. 3, pp. 1599–1610, 2018.

[46] M. Tomita, T. Ayabe, E. Chosa, and K. Nakamura, “Prognostic significance of pre- and postoperative Glasgow prognostic score for patients with non-small cell lung cancer,” *Anticancer Research*, vol. 34, no. 6, pp. 3137–3140, 2014.

[47] A. G. Jiang, H. L. Chen, and H. Y. Lu, “Comparison of Glasgow prognostic score and prognostic index in patients with advanced non-small cell lung cancer,” *Journal of Cancer Research and Clinical Oncology*, vol. 141, no. 3, pp. 563–568, 2015.

[48] Q. Guo and Y. Hua, “The assessment of circulating cell-free DNA as a diagnostic tool for breast cancer: an updated systematic review and meta-analysis of quantitative and qualitative ssays,” *Clinical Chemistry and Laboratory Medicine*, vol. 59, no. 9, pp. 1479–1500, 2021.

[49] K. Inagaki, M. Kanda, K. Nakanishi et al., “Accurate prediction of prognosis after radical resection of gastric cancer by the modified systemic inflammation score; a multicenter dataset analysis,” *World Journal of Surgery*, vol. 45, no. 8, pp. 2513–2520, 2021.

[50] J. You, H. Zhang, Y. Shen et al., “Impact of platelet to lymphocyte ratio and metabolic syndrome on the prognosis of colorectal cancer patients,” *Oncotargets and Therapy*, vol. 10, pp. 2199–2208, 2017.